KALA BIO, Inc.

KALA

NASDAQ

Healthcare

Biotechnology

Arlington, MA, US38 employeeskalarx.com

$0.17

+0.01(4.11%)

Mkt Cap $4M

$0.16

$19.63

52-Week Range

At a Glance

AI-generated

8-K

KALA BIO, Inc. entered into a Platform Development and Exclusive License Agreement with 2624465 Ontario Inc. o/a Younet AI on March 3, 2026, obtaining a worldwide exclusive license to the Researgency Platform for 12 months with renewal options. The Company will issue 5,000,000 shares of common stock and pay up to $530,000 in cash for the initial term, plus an option to acquire Younet for $55,000,000.

$4M

Market Cap

$790.9K

Revenue

-$112M

Net Income

Employees38

Fundamentals

How The Business Makes Money

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Feb 19, 2026

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 16, 2026, David Lazar notified KALA BIO, I

Management Change

Feb 4, 2026

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 2, 2026, David Lazar tendered his resignat

Delisting

Jan 22, 2026

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 20, 2026, KALA Bio, Inc. (the “ Company ”) recei

Material Agreement

Mar 3, 2026

, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regu

Material Agreement

Jan 7, 2026

. Entry into a Material Definitive Agreement. On January 8, 2026, KALA BIO, Inc. (the “ Company ”), entered into an At The Market Offering Agreement (the “ Sale

Peer Companies

Company	Price	Change	Market Cap	P/E
SNGXSoligenix, Inc.	$1.14	-0.87%	$11M	-0.5
VYNEVYNE Therapeutics Inc.	$0.61	+0.58%	$10M	-1.0
IBOImpact BioMedical Inc.	$0.60	-1.55%	$8M	—
KTTAPasithea Therapeutics Cor...	$0.77	+3.49%	$6M	-0.4
OGENOragenics, Inc.	$0.58	+4.91%	$3M	—
AIMAIM ImmunoTech Inc.	$0.60	+9.05%	$2M	—
CANFCan-Fite BioPharma Ltd.	$3.10	+0.49%	$2M	—
ENSCEnsysce Biosciences, Inc.	$0.60	+9.45%	$2M	-0.2

Analyst View

Company Profile

CIK0001479419

ISINUS4831192020

CUSIP483119103

Phone781 996 5252

Address1167 Massachusetts Avenue, Arlington, MA, 02476, US

SEC EDGAR